13F Holdings
中文EN

ANTX AN2 Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1880438 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.5%
TTM EPS YoY19.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-51.3%
ROA-46.7%
ROIC (approx.)-60.6%
Asset turnover—

Leverage & solvency

Liabilities / assets7.9%
Debt / equity0.00x
Current ratio10.48x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$24.77M$40.49M$54.87M$28.51M$16.16M
SG&A expense$13.34M$14.07M$14.76M$12.75M$4.67M
Operating income-$38.11M-$56.79M-$69.64M-$42.26M-$21.57M
Income tax$0$0$0$0$0
Net income-$35.17M-$51.32M-$64.73M-$40.96M-$21.54M
EPS (basic)-1.16-1.72-2.74-2.79-10.64
EPS (diluted)-1.16-1.72-2.74-2.79-10.64
Weighted avg. shares (diluted)30.22M29.83M23.60M15.34M2.64M
Balance sheet
Cash & equivalents$19.94M$21.35M$15.65M$27.22M$12.10M
Short-term investments$38.06M$62.27M$91.65M$68.84M$46.46M
Current assets$59.94M$86.26M$110.51M$98.62M$60.11M
Total assets$61.95M$92.09M$138.74M$102.56M$65.32M
Current liabilities$8.72M$10.24M$14.04M$7.19M$3.40M
Total liabilities$8.89M$10.24M$14.04M$7.19M$3.41M
Shareholders' equity$53.06M$81.85M$124.70M$95.37M-$47.41M
Shares outstanding27.41M29.92M29.74M19.40M2.73M
Cash flow statement
Operating cash flow-$29.83M-$49.26M-$53.29M-$33.46M-$20.48M
Investing cash flow$28.31M$54.59M-$43.28M-$21.77M-$50.02M
Financing cash flow$113,000$372,000$84.99M$70.36M$78.53M
Stock-based compensation$6.25M$8.34M$8.41M$4.39M$974,000

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.